A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization

Jose Baselga

Research output: Contribution to journalReview articleResearchpeer-review

39 Citations (Scopus)

Abstract

Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies. Copyright © 2002 Cell Press.
Original languageEnglish
Pages (from-to)93-95
JournalCancer Cell
Volume2
Issue number2
DOIs
Publication statusPublished - 1 Jan 2002

Fingerprint Dive into the research topics of 'A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization'. Together they form a unique fingerprint.

Cite this